Fezolinetant

Fezolinetant
Above: molecular structure of fezolinetant Below: 3D representation of a fezolinetant molecule
Clinical data
Trade namesVeozah, Veoza
Other namesESN-364
AHFS/Drugs.comMonograph
MedlinePlusa623051
License data
Pregnancy
category
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding51%[8]
MetabolismCYP1A2, (CYP2C9, CYP2C19 to lesser extent)[5]
MetabolitesES259564[9]
Elimination half-life9.6h[5]
ExcretionUrine 76.9%, feces 14.7%[10]
Identifiers
IUPAC name
  • (4-fluorophenyl)-[(8R)-8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]methanone
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC16H15FN6OS
Molar mass358.40 g·mol−1
3D model (JSmol)
SMILES
  • C[C@@H]1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)F)C4=NC(=NS4)C
InChI
  • InChI=1S/C16H15FN6OS/c1-9-13-19-20-14(15-18-10(2)21-25-15)23(13)8-7-22(9)16(24)11-3-5-12(17)6-4-11/h3-6,9H,7-8H2,1-2H3/t9-/m1/s1
  • Key:PPSNFPASKFYPMN-SECBINFHSA-N

Fezolinetant, sold under the brand name Veozah, among others, is a medication used for the treatment of hot flashes (vasomotor symptoms) due to menopause.[5][11] It is a small-molecule, selective neurokinin-3 (NK3) receptor antagonist taken by mouth.[5] It was developed by Astellas Pharma, which acquired it from Ogeda (formerly Euroscreen) in April 2017.[12][13][14]

The most common side effects of fezolinetant include abdominal pain, diarrhea, insomnia, back pain, hot flush, and elevated hepatic transaminases.[11]

Fezolinetant was approved for medical use in the United States in May 2023,[11] and it was approved in the European Union in December 2023.[6][7] Fezolinetant is the first NK3 receptor antagonist approved by the US Food and Drug Administration (FDA) to treat moderate to severe hot flashes from menopause.[11] The FDA considers it to be a first-in-class medication.[15]

  1. ^ a b "Veoza APMDS". Therapeutic Goods Administration (TGA). 6 March 2024. Retrieved 7 March 2024.
  2. ^ "Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024". Federal Register of Legislation. 30 May 2024. Retrieved 10 June 2024.
  3. ^ "Veozah product information". Health Canada. 3 December 2024. Retrieved 27 December 2024.
  4. ^ "Summary Basis of Decision for Veozah". Drug and Health Products Portal. 24 February 2025. Retrieved 10 July 2025.
  5. ^ a b c d e "Veozah – fezolinetant tablet, film coated". DailyMed. 19 May 2023. Archived from the original on 25 May 2023. Retrieved 24 May 2023.
  6. ^ a b "Veoza EPAR". European Medicines Agency (EMA). 7 December 2023. Archived from the original on 26 December 2023. Retrieved 27 December 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  7. ^ a b "Veoza PI". Union Register of medicinal products. 12 December 2023. Archived from the original on 13 December 2023. Retrieved 26 December 2023.
  8. ^ "Fezolinetant". Archived from the original on 7 July 2023. Retrieved 7 July 2023.
  9. ^ "Pharmacokinetic Study of Fezolinetant - an Open-Label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics and Safety of Fezolinetant in Healthy Chinese Female Subjects". 15 April 2022. Archived from the original on 7 July 2023. Retrieved 7 July 2023.
  10. ^ "Fezolinetant". DrugBank.com. Archived from the original on 7 July 2023. Retrieved 7 July 2023.
  11. ^ a b c d "FDA Approves Novel Drug to Treat Moderate to Severe Hot Flashes Caused by Menopause". U.S. Food and Drug Administration (FDA) (Press release). 12 May 2023. Archived from the original on 13 May 2023. Retrieved 13 May 2023. This article incorporates text from this source, which is in the public domain.
  12. ^ "Astellas to Acquire Ogeda SA" (Press release). Astellas Pharma. Archived from the original on 5 November 2021. Retrieved 5 November 2021 – via PR Newswire.
  13. ^ Hoveyda HR, Fraser GL, Dutheuil G, El Bousmaqui M, Korac J, Lenoir F, et al. (July 2015). "Optimization of Novel Antagonists to the Neurokinin‑3 Receptor for the Treatment of Sex-Hormone Disorders (Part II)". ACS Medicinal Chemistry Letters. 6 (7): 736–740. doi:10.1021/acsmedchemlett.5b00117. PMC 4499830. PMID 26191358.
  14. ^ "Fezolinetant – Ogeda". AdisInsight. Archived from the original on 5 November 2021. Retrieved 5 November 2021.
  15. ^ New Drug Therapy Approvals 2023. U.S. Food and Drug Administration (FDA) (Report). January 2024. Archived from the original (PDF) on 10 January 2024. Retrieved 9 January 2024.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.